Advertisement
tecaLAB
tecaLAB

Italian Stem Cell Controversy

Italian government officials and scientists clashed last week with a controversial stem cell researcher over details of an upcoming clinical trial.

By | July 16, 2013

The Palazzo Montecitorio is home to one house of the Italian Parliament.WIKIMEDIA COMMONS, RUANDABIT

A panel of Italian science administrators and stem cell scientists convened Friday (July 12) to discuss with Davide Vannoni, the president of the Stamina Foundation, the details of a government-sponsored clinical trial of a controversial stem cell treatment, reported ScienceInsider.

Italian stem cell scientists have criticized Stamina’s treatment as being untested, and opponents of the trial are hoping that recent news concerning allegedly plagiarized figures in a patent application filed by Vannoni will steer public funds away from the research. One critic, Massimo Dominici, president-elect of the International Society for Cellular Therapy, told ScienceInsider that the proposed trial is a “waste of money.”

Despite the scrutiny, the Italian Parliament decided in May that a small group of patients could continue treatment, and has set aside €3 million for the 18-month-long trial. On July 1, Italian Health Minister Beatrice Lorenzin appointed a panel, which includes the heads of the Superior Health Institute, the National Italian Transplant Centre, and the Italian Medicines Agency, as well as several Italian stem cell scientists, to oversee the trial. Though the panel requested Vannoni hand over standardized protocols describing the how Stamina’s largely unpublished treatment works, he has yet to do so, claiming “seven years of innovation cannot be standardized overnight,” according to ScienceInsider. The details of Friday’s meeting between Vannoni and the panel have not been released.

Stamina “must present the protocols as soon as possible,” Maria Chiara Carrozza, Italy’s minister of universities and research, told ScienceInsider. “Anything else would be neither scientific nor ethical.”

Vannoni has already indicated to the panel that he will not change his protocol for fabricating stem cells to meet an international quality standard called the Good Manufacturing Practice. According to ScienceInsider, he has also told the panel that cells for the trial must be produced under supervision of a Stamina biologist and that the trial should include patients with three different diseases: amyotrophic lateral sclerosis, cerebral palsy in infants, and a degenerative disease with non-neurological origin. He has indicated that if his conditions are not met, he may move the research abroad.

 

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Life Technologies